Funding round brings in $25 million for Versartis

01/16/2013 | American City Business Journals

Versartis secured $25 million from new and existing investors in a Series C financing round. Proceeds will support clinical trials of VRS-317, an investigational once-monthly form of recombinant human growth hormone designed for children with growth hormone deficiency. "With this substantial funding, we are able to continue our comprehensive development program for VRS-317, including obtaining proof-of-concept efficacy results and preparing for the launch of a Phase III trial in 2014," Versartis CEO Jeffrey Cleland said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID